Additionally, inhibition of SLC1A5-mediated glutamine transport by knockdown of SLC1A5 or adding SLC1A5 inhibitor L-γ-glutamyl-p-nitroanilide (GPNA) attenuates mTOR activation and proliferation of breast cancer cells, and these inhibitory effects are more prominent in TNBC tumor cells compared to luminal subtypes (88). The gene discussed is SLC1A5; the disease is breast carcinoma.